Under: Sexual Health
Best Peptides for Sexual Anxiety
Addressing performance anxiety and psychological barriers to sexual function.
Sexual anxiety refers to performance-related psychological barriers that can interfere with sexual function, distinct from physiological erectile dysfunction. Research peptides like PT-141 (Bremelanotide) are being studied for their potential to address anxiety-related sexual dysfunction by activating melanocortin receptors in the central nervous system—a mechanism that differs from conventional pharmaceutical approaches by targeting arousal pathways directly rather than peripheral blood flow.
PT-141 research protocols typically involve subcutaneous or intranasal administration, with timing considerations around anticipated sexual activity rather than continuous dosing. Individual response variability is significant in research contexts, and protocols often employ escalating dose schemes to assess tolerance and efficacy.
Peptides Studied for Sexual Anxiety
| Peptide | Evidence | Notes | Actions |
|---|---|---|---|
| PT-141 (Bremelanotide) PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. | medium | — | |
| PT-141 (Bremelanotide) PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. | medium | — |
PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.
PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.